Alnylam Switzerland GMBH

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded to help those people who lack adequate treatment options live fuller, healthier lives. Patients are at the core of everything we do. Their needs inspire us to innovate and take action and their stories keep us focused on that overriding mission. We feel a deep connection to the people we seek to serve. We provide, support, or sponsor:
•Patient education programs through partnered events and Alnylam Ambassadors
•Patient advocacy organizations around the world
•Funding to patient groups through grants
•Cultural events that nurture awareness and learning about rare diseases
•Employee initiatives focused on raising disease awareness